15 February 2024 - To address and maintain the financial sustainability of the national insurance system, the Government rolled out several new repricing schemes and stricter repricing rules for regular price reductions.

At the end of 2023, Japan’s Central Social Insurance Medical Council (Chuikyo) approved the outlines of its drug pricing and repricing reform for national health insurance listed drugs that will take effect in FY 2024 and FY 2025. All proposals covered in the reform are expected to be released before April 2024.

Read Pharmaceutical Technology article